Stockscreener 앱 받기
0.3366
6.34%
-0.0214
전일 마감가:
$0.358
열려 있는:
$0.384
하루 거래량:
9.90M
Relative Volume:
15.22
시가총액:
$39.26M
수익:
-
순이익/손실:
$-37.65M
주가수익비율:
-0.2016
EPS:
-1.67
순현금흐름:
$-24.14M
1주 성능:
-52.22%
1개월 성능:
-69.52%
6개월 성능:
-81.37%
1년 성능:
-73.80%
1일 변동 폭
$0.315
$0.3857
1주일 범위
$0.30
$0.8299
52주 변동 폭
$0.30
$4.28
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
명칭
Reviva Pharmaceuticals Holdings Inc
전화
(408) 501-8881
주소
10080 N WOLFE ROAD, CUPERTINO
RVPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.3354 | 39.26M | 0 | -37.65M | -24.14M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.21 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.70 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.38 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.43 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-20 | 개시 | ROTH MKM | Buy |
| 2023-06-08 | 개시 | The Benchmark Company | Speculative Buy |
| 2022-01-24 | 개시 | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Ameriprise Financial Inc. Takes $84,000 Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
RVPH: Open Label Extension Results & Key Opinion Leader Discussion - MSN
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Pharma Reveals New Pipeline Updates at Major Neuroscience Conference - Stock Titan
Data Readout Positive from Trial of New Schizophrenia Drug - streetwisereports.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals (RVPH) Receives Buy Rating from D. Boral - GuruFocus
Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - MarketScreener
Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq
Reviva reports positive year-long schizophrenia drug study - Investing.com Australia
Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia - TipRanks
Reviva Pharmaceuticals Reports Positive 1-Year Phase 3 Results for Brilaroxazine in Schizophrenia, Highlighting Efficacy and Safety - Nasdaq
Reviva Announces Positive Full Dataset for 1-Year Phase 3 - GlobeNewswire
Breakthrough in Schizophrenia Treatment: Phase 3 Trial Reveals Sustained Efficacy Over 12 Months - Stock Titan
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Shares Sold by Millennium Management LLC - Defense World
Reviva Pharmaceuticals Launches $50M At-Market Offering - TipRanks
Reviva Pharmaceuticals Holdings IncEnters Into At Market Issuance Sales AgreementSEC Filing - marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings? - Defense World
Roth Capital Issues Positive Forecast for RVPH Earnings - Defense World
D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00 - Defense World
Reviva Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Reviva stock target cut to $3 on cash concerns, retains Buy rating - Investing.com Australia
Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - NewsBreak: Local News & Alerts
Reviva to Participate in Upcoming Investor Conferences in May 2025 - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Low - GuruFocus
Reviva Pharmaceuticals (RVPH) Sees Price Target Reduction Amid Funding Concerns | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Lowers Price Target | RVPH Stock News - GuruFocus
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Tow - GuruFocus
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Towards Approval | RVPH Stock News - GuruFocus
Major Milestone: 446 Patients Complete Reviva's Schizophrenia Drug Trial, Full Results Expected Q2 2025 - Stock Titan
Reviva to Participate in the A.G.P. Healthcare Company Showcase - GlobeNewswire
Tower Research Capital LLC TRC Has $48,000 Stock Holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday - Defense World
Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5% - Defense World
Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan
Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX
Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com
Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire
Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan
Reviva Pharmaceuticals Holdings Inc (RVPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.37%
0.65%
자본화:
|
볼륨(24시간):